507
Participants
Start Date
April 30, 2009
Primary Completion Date
November 30, 2010
Study Completion Date
November 30, 2010
Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)
Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
Ethinyl estradiol, Levonorgestrel (Miranova)
Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
Placebo Match to SH T00658ID
Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
Placebo Match to SH D593B
Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
Metro Manila
Torino
Pittsburgh
Philadelphia
Milan
Hamburg
Brescia
Winston-Salem
Sandy Springs
Hialeah
Udine
Leesburg
Magdeburg
Bologna
Modena
Essen
Cologne
Siena
La Crosse
Francavilla Fontana
Freiburg im Breisgau
Idaho Falls
Tucson
San Diego
Temuco
Langley
Toronto
Pointe-Claire
Ste-Foy
Regina
Santiago
Talcahuano
Cebu
Cebu City
Davao City
Metro Manila
Quezon City
Leipzig
Bernburg
Perugia
Roma
Lead Sponsor
Bayer
INDUSTRY